creators_name: Ding, C
creators_name: Li, J
creators_name: Zhang, X
creators_id: chding@utas.edu.au
creators_id: 
creators_id: 
type: article
datestamp: 2008-04-01 03:00:29
lastmod: 2008-07-18 10:43:11
metadata_visibility: show
title: Bertilimumab (Cambridge Antibody Technology Group)
ispublished: pub
subjects: 320503
full_text_status: restricted
abstract: Cambridge Antibody Technology (CAT) is developing
bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.
date: 2004
date_type: published
publication: Current Opinion in Investigational Drugs
volume: 5
number: 11
pagerange: 1213-1219
refereed: TRUE
issn: 1472-4472
official_url: http://www.biomedcentral.com/1472-4472/5?issue=11
citation: Ding, C and Li, J and Zhang, X (2004) Bertilimumab (Cambridge Antibody Technology Group). Current Opinion in Investigational Drugs, 5 (11). pp. 1213-1219. ISSN 1472-4472
document_url: http://eprints.utas.edu.au/3608/1/bertilimumab.pdf